Innoviva (INVA)
(Delayed Data from NSDQ)
$19.83 USD
+0.09 (0.46%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $19.84 +0.01 (0.05%) 6:30 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.83 USD
+0.09 (0.46%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $19.84 +0.01 (0.05%) 6:30 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
by Zacks Equity Research
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Moving Average Crossover Alert: Innoviva (INVA)
by Zacks Equity Research
Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Theravance Up as CHMP Backs Trelegy Elipta Line Extension
by Zacks Equity Research
Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.
AstraZeneca's Bevespi Unimpressive in Phase III COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
by Zacks Equity Research
Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
by Zacks Equity Research
AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
by Zacks Equity Research
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
by Zacks Equity Research
The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
by Zacks Equity Research
Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
Illumina (ILMN) Catches Eye: Stock Soars 14.8%
by Zacks Equity Research
Illumina (ILMN) was a big mover last session, as the company saw its shares rise over 14% on the day.
Moving Average Crossover Alert: Innoviva (INVA)
by Zacks Equity Research
Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Can The Uptrend Continue for Innoviva (INVA)?
by Zacks Equity Research
Investors certainly have to be happy with Innoviva, Inc. (INVA) and its short term performance